

DUPILUMAB

BRAND NAME	DUPIXENT
DRUG CLASS	IL-4 and IL-13 inhibitor, monoclonal antibody (human)
AVAILABILITY	Prefilled syringe and pen contains 200 mg/1.14 mL or 300 mg/2 mL of dupilumab. Also contains arginine, histidine/histidine hydrochloride monohydrate, polysorbate-80, sodium acetate, sucrose and acetic acid. ¹ The solution is clear to slightly opalescent and colourless to pale yellow. ¹
pH	5.9 ¹
PREPARATION	Ready to use. Allow 30 minutes for the 200 mg syringe or pen and 45 minutes for the 300 mg syringe or pen to reach room temperature. Do not shake. ¹
STABILITY	Store at 2 to 8 °C. Do not freeze. Protect from light. ¹ Stable for 14 days at room temperature up to 25 °C. Do not return to the fridge. ¹
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Inject into the stomach, upper arm or front thigh. Rotate the site of the injection. ¹ Suitable for self administration after appropriate patient education. ¹
IV injection	Not recommended
IV infusion	Not recommended
COMPATIBILITY	No information
INCOMPATIBILITY	No information
SPECIAL NOTES	Injection-site reactions are very common. ¹ Hypersensitivity reactions have been reported. ¹

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 05/07/2022.